Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: betty moyers who wrote (19424)	3/9/1999 8:18:00 AM
From: Mkilloran	Read Replies (2) \| Respond to of 23519

betty...and for the new followers Alibra in Phase III FDA trials is much less expensive to produce and does not need to be kept in the fridge...stores at room temp..is smaller and more effective than MUSE. Vivus is also progressing with Gene Therapy at Alber tEinstein Medical Center in NYC and is working on a few more products beyond their latest announcement of a Female sexual dysfunction product . This stock has ben pushed down for too long..sales of Muse in Europe are getting 25% of the market when selling aginst Viagra. That alone is a great piece of a $4 billion worldwide ED market. Astra and Janssen have developed an effective marketing program to the ED patients that can not use Viagra due to conflicts with other meds like nitro as well as those that are not successful with using Viagra. Next steps are to get Astra/Zeneca or another large pharm co to market Muse in the USA and Japan....while they rollout Muse around the world. OLD news for those that have followed Vivus for the last 6-9 months for the new investors this stock has a lot of potential to move to double digits fast...... Let's see if the shorts remember KTEL......